-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On April 26, many pharmaceutical companies released their 2022 first quarter performance reports
.
According to the report released by the pharmaceutical company on the 26th, the company's performance is happy and worrying about the merger
.
Tigermed disclosed in the report for the first quarter of 2022 that during the reporting period, the company achieved operating income of 1.
818 billion yuan, a year-on-year increase of 101.
55%, and realized a net profit attributable to shareholders of the listed company of 518 million yuan, a year-on-year increase of 13.
82%.
The company's shareholders' net profit after deducting non-recurring gains and losses was 378 million yuan, a year-on-year increase of 65.
31%, and basic earnings per share were 0.
6 yuan
.
Xianju Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 1.
049 billion yuan, a year-on-year increase of 4.
76%; net profit was about 128 million yuan, a year-on-year increase of 15.
47%; basic earnings per share were 0.
13 yuan, a year-on-year increase of 18.
18%
.
From January to December 2021, Xianju Pharmaceutical's operating income is composed of: pharmaceuticals account for 99.
48%
.
Jiudian Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 449 million yuan, a year-on-year increase of 61.
47%; net profit was about 55.
97 million yuan, a year-on-year increase of 20.
49%; basic earnings per share were 0.
24 yuan, a year-on-year increase of 20%
.
From January to December 2020, the operating income of Jiudian Pharmaceutical was composed of: pharmaceutical manufacturing industry accounted for 99.
75%
.
According to the report released by Renhe Pharmaceuticals for the first quarter of 2022, in the first quarter of 2022, the company achieved operating income of 1.
311 billion yuan, a year-on-year increase of 7.
66%; net profit attributable to shareholders of the listed company was 156 million yuan, a year-on-year increase of 1.
95%
.
Xinguang Pharmaceutical disclosed the first quarter report of 2022 on the evening of April 26, saying that during the reporting period, the company realized a net profit attributable to shareholders of listed companies of 42.
8191 million yuan, a year-on-year increase of 9.
85%
.
Lisheng Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 306 million yuan, a year-on-year decrease of 6.
45%; net profit was about 41.
95 million yuan, a year-on-year increase of 16.
36%; basic earnings per share were 0.
23 yuan, a year-on-year increase of 15%
.
From January to December 2021, the composition of Lisheng Pharmaceutical's operating income is: the pharmaceutical industry accounts for 100.
0%
.
Jiaying Pharmaceutical announced the report for the first quarter of 2022 that the company achieved operating income of 121 million yuan, a year-on-year decrease of 1.
13%; net profit attributable to shareholders of the listed company was 2.
5357 million yuan, a year-on-year decrease of 67.
34%
.
Foci Pharmaceuticals released its first-quarter results announcement, saying that in the first quarter of 2022, revenue was about 237 million yuan, a year-on-year increase of 33.
5%; net profit was about 21.
5 million yuan, a year-on-year decrease of 6.
96%; basic earnings per share were 0.
0421 yuan, a year-on-year decrease of 6.
86%
.
In addition, from January to December 2021, the operating income of Foci Pharmaceuticals is composed of: the pharmaceutical industry accounts for 97.
66%, the food industry accounts for 1.
46%, and the consumer goods industry accounts for 0.
88%
.
Fosun Pharma released a first-quarter performance report saying that the company achieved a net profit of 463 million yuan in the first quarter of 2022, a year-on-year decrease of 45.
41%
.
During the reporting period, benefiting from the growth contribution of Fubitai, Hanquyou (trastuzumab for injection), Su Kexin (avatrombopag maleate tablets), heparin series preparations and other products, the company achieved business The income was 10.
382 billion yuan, a year-on-year increase of 28.
87%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 801 million yuan, an increase of 143 million yuan or 1.
73% year-on-year
.
However, due to market fluctuations and other factors, the stock price of financial assets such as BNTX shares held by the company at the end of the reporting period decreased compared with the end of 2021.
The loss from changes in fair value of these financial assets caused the non-recurring profit and loss of the Group to be -338 million during the reporting period.
The non-recurring profit and loss in the same period of the previous year was 189 million yuan, a year-on-year decrease of 527 million yuan
.
Puluo Pharmaceutical disclosed in the report for the first quarter of 2022 that during the reporting period, the company achieved operating income of 2.
101 billion yuan, a year-on-year increase of 6.
85%; net profit of 152 million yuan, a year-on-year decrease of 29.
96%; basic earnings per share of 0.
1291 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the report released by the pharmaceutical company on the 26th, the company's performance is happy and worrying about the merger
.
Tigermed disclosed in the report for the first quarter of 2022 that during the reporting period, the company achieved operating income of 1.
818 billion yuan, a year-on-year increase of 101.
55%, and realized a net profit attributable to shareholders of the listed company of 518 million yuan, a year-on-year increase of 13.
82%.
The company's shareholders' net profit after deducting non-recurring gains and losses was 378 million yuan, a year-on-year increase of 65.
31%, and basic earnings per share were 0.
6 yuan
.
Xianju Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 1.
049 billion yuan, a year-on-year increase of 4.
76%; net profit was about 128 million yuan, a year-on-year increase of 15.
47%; basic earnings per share were 0.
13 yuan, a year-on-year increase of 18.
18%
.
From January to December 2021, Xianju Pharmaceutical's operating income is composed of: pharmaceuticals account for 99.
48%
.
Jiudian Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 449 million yuan, a year-on-year increase of 61.
47%; net profit was about 55.
97 million yuan, a year-on-year increase of 20.
49%; basic earnings per share were 0.
24 yuan, a year-on-year increase of 20%
.
From January to December 2020, the operating income of Jiudian Pharmaceutical was composed of: pharmaceutical manufacturing industry accounted for 99.
75%
.
According to the report released by Renhe Pharmaceuticals for the first quarter of 2022, in the first quarter of 2022, the company achieved operating income of 1.
311 billion yuan, a year-on-year increase of 7.
66%; net profit attributable to shareholders of the listed company was 156 million yuan, a year-on-year increase of 1.
95%
.
Xinguang Pharmaceutical disclosed the first quarter report of 2022 on the evening of April 26, saying that during the reporting period, the company realized a net profit attributable to shareholders of listed companies of 42.
8191 million yuan, a year-on-year increase of 9.
85%
.
Lisheng Pharmaceutical released a first-quarter results announcement saying that in the first quarter of 2022, revenue was about 306 million yuan, a year-on-year decrease of 6.
45%; net profit was about 41.
95 million yuan, a year-on-year increase of 16.
36%; basic earnings per share were 0.
23 yuan, a year-on-year increase of 15%
.
From January to December 2021, the composition of Lisheng Pharmaceutical's operating income is: the pharmaceutical industry accounts for 100.
0%
.
Jiaying Pharmaceutical announced the report for the first quarter of 2022 that the company achieved operating income of 121 million yuan, a year-on-year decrease of 1.
13%; net profit attributable to shareholders of the listed company was 2.
5357 million yuan, a year-on-year decrease of 67.
34%
.
Foci Pharmaceuticals released its first-quarter results announcement, saying that in the first quarter of 2022, revenue was about 237 million yuan, a year-on-year increase of 33.
5%; net profit was about 21.
5 million yuan, a year-on-year decrease of 6.
96%; basic earnings per share were 0.
0421 yuan, a year-on-year decrease of 6.
86%
.
In addition, from January to December 2021, the operating income of Foci Pharmaceuticals is composed of: the pharmaceutical industry accounts for 97.
66%, the food industry accounts for 1.
46%, and the consumer goods industry accounts for 0.
88%
.
Fosun Pharma released a first-quarter performance report saying that the company achieved a net profit of 463 million yuan in the first quarter of 2022, a year-on-year decrease of 45.
41%
.
During the reporting period, benefiting from the growth contribution of Fubitai, Hanquyou (trastuzumab for injection), Su Kexin (avatrombopag maleate tablets), heparin series preparations and other products, the company achieved business The income was 10.
382 billion yuan, a year-on-year increase of 28.
87%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 801 million yuan, an increase of 143 million yuan or 1.
73% year-on-year
.
However, due to market fluctuations and other factors, the stock price of financial assets such as BNTX shares held by the company at the end of the reporting period decreased compared with the end of 2021.
The loss from changes in fair value of these financial assets caused the non-recurring profit and loss of the Group to be -338 million during the reporting period.
The non-recurring profit and loss in the same period of the previous year was 189 million yuan, a year-on-year decrease of 527 million yuan
.
Puluo Pharmaceutical disclosed in the report for the first quarter of 2022 that during the reporting period, the company achieved operating income of 2.
101 billion yuan, a year-on-year increase of 6.
85%; net profit of 152 million yuan, a year-on-year decrease of 29.
96%; basic earnings per share of 0.
1291 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
